NCT00442923撤回2 期
Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse
Aaron J. Janowsky1 个研究点 分布在 1 个国家开始时间: 2007年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
研究概览
简要总结
The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Must have entered treatment into the outpatient Clinical Addiction Rehabilitation Section (CARS) through the US Portland Veterans Affairs Medical Center
- •Must meet the clinical definition for methamphetamine dependence
- •Self-reported methamphetamine use within 10 days of entering the study
- •Must be able to understand and sign the consent form
排除标准
- •Dependent on any other drug except nicotine, caffeine, marijuana and alcohol
- •Pregnant or nursing mothers
- •Psychosis
- •Any serious medical condition that could be aggravated by the study protocol (Allergic reaction, Hypotension, Asthma, Bronchospastic conditions, Angina, Bronchitis, Emphysema, Bradycardia, Heart or blood vessel disease, Diabetes mellitus, Low blood sugar, Kidney disease, Liver disease or Overactive thyroid)
- •History of withdrawal seizures or delirium tremors
- •Use of MAO inhibitors within the last two weeks
- •Considerable hepatocellular injury, including cirrhosis of the liver or liver function test levels higher than 2 times normal
研究组 & 干预措施
CTRL
Placebo Comparator
干预措施: Coreg (Drug)
TREAT
Experimental
干预措施: Coreg (Drug)
研究者
Aaron J. Janowsky
Director, Methamphetamine Abuse Research Center
Oregon Health and Science University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk StratificationBreast CancerNCT02177175Memorial Sloan Kettering Cancer Center82
尚未招募
早期 1 期
Clinical Study Evaluating the Effect of Carvedilol in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisNCT06108518Tanta University70
招募中
3 期
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityCardiotoxicityHER2/Neu PositiveMetastatic Malignant Neoplasm in the BrainRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7NCT03418961SWOG Cancer Research Network491
已完成
3 期
Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular DystrophyHeart FailureCardiomyopathyDuchenne Muscular DystrophyNCT01648634Assistance Publique - Hôpitaux de Paris51
已完成
2 期
Study the preventive effect of Carvedilol therapy against Adriamycin-induced acute cardiotoxicity in breast cancer patients by measurement of myocardial deformation indexCongestive heart failureCondition 1: breast cancer. Condition 2: heart failure.Breast, unspecifiedIRCT2013093012924N1Vice chancellor for research, Mashhad University of Medical Sciences70